## NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## **Single Technology Appraisal (STA)**

# Methylnaltrexone for the treatment of opioid-induced bowel dysfunction in advanced illness or palliative care

## Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Wyeth Pharmaceuticals	Age Concern Cymru
(methylnaltrexone)	Board of Community Health Councils in Wales
Patient/carer groups	British National Formulary
Action on Pain	Cancer Care Cymru
Afiya Trust	Department of Health, Social Services
Age Concern England	and Public Safety for Northern Ireland
Black Health Agency	Medicines and Healthcare products
<ul> <li>Bladder and Bowel Foundation</li> </ul>	Regulatory Agency
<ul> <li>British Ethnic Health Awareness</li> </ul>	<ul> <li>National Association of Primary Care</li> </ul>
Foundation (BEHAF)	<ul> <li>National Public Health Service for</li> </ul>
CANCERactive	Wales
Cancerbackup	NHS Alliance
Cancer Black Care	NHS Confederation
Cancer Equality	NHS Purchasing and Supply Agency
Cancer Voices	NHS Quality Improvement Scotland
<ul> <li>Chinese National Healthy Living</li> </ul>	Scottish Medicines Consortium
Centre	
<ul> <li>Confederation of Indian Organisations</li> </ul>	Comparator manufacturers
CORE (Digestive Disorders	Actavis UK (glycerol suppositories)
Foundation)	Boehringer Ingelheim (bisacodyl
Counsel and Care	suppositories)
Equalities National Council	E.C. DeWitt (phosphates enema)
Helen Rollason Heal Cancer Charity	Essential Generics (arachis oil enema,
Help the Aged	phosphates enema)
Help the Hospices	Forest Laboratories UK (arachis oil
Macmillan Cancer Support	enema, phosphates enema)
Maggie's Centres	IVAX Pharmaceuticals UK (glycerol auppacitorics)
Marie Curie Cancer Care	suppositories)
Motor Neurone Disease Association	Martindale pharma (bisacodyl suppositorios)
Muslim Council of Great Britain	suppositories, glycerol suppositories)
Muslim Health Network	Reckitt Benckiser (Senokot direct relief
National Cancer Alliance	suppositories)
<ul> <li>National Council for Palliative Care</li> </ul>	Teva UK (glycerol suppositories)

National Institute for Health and Clinical Excellence

Matrix for the appraisal of methylnaltrexone for the treatment of opioid-induced bowel dysfunction in advanced illness or palliative care

Issue date: February 2009

#### Consultees Commentators (no right to submit or appeal) Pain Concern Thornton & Ross (glycerol Pain Relief Foundation suppositories) South Asian Health Foundation Relevant research groups Specialised Healthcare Alliance Institute of Cancer Research Sue Ryder Care MRC Clinical Trials Unit Tenovus Cancer Information Centre National Cancer Research Institute Professional groups • Association for Palliative Medicine National Cancer Research Network Association of Cancer Physicians National Institute for Health Research British Association for Services to the Policy Research Institute on Ageing and Elderly **Ethnicity** Research Institute for the Care of Older British Geriatrics Society People British Oncological Association (BOA) • United Kingdom Clinical Research • British Pain Society Network British Psychosocial Oncology Society (BPOS) **Evidence Review Group** Cancer Networks Pharmacists Forum Liverpool Reviews & Implementation Cancer Research UK Group, University of Liverpool Palliative Care Pharmacists Network National Institute for Health Research • Royal College of General Practitioners Health Technology Assessment Royal College of Nursing Programme Royal College of Pathologists Royal College of Physicians **Associated Guideline Groups** Royal Pharmaceutical Society None Royal Society of Medicine -Intellectual Disabilities Forum Associated Public Health Groups United Kingdom Clinical Pharmacy None Association United Kingdom Oncology Nursing Society Others Department of Health Richmond and Twickenham PCT Sunderland Teaching PCT Welsh Assembly Government

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists

**Appendix B** 

contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

#### **Definitions:**

### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

## Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

## Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

National Institute for Health and Clinical Excellence Matrix for the appraisal of methylnaltrexone for the treatment of opioid-induced bowel dysfunction in advanced illness or palliative care Issue date: February 2009

<sup>&</sup>lt;sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.